It’s time to better understand the galaxy of channels we use to shop online and in stores. Photo via Pexels

Back in the Paleolithic Age of online marketing — say, 15 years ago — the idea of online sales as a significant business vehicle for brands such as Target or Walmart was almost unimaginable. Shopping meant going to a store, because stores were where sales happened.

Today, people shop with their computers, via watches and phones, even through their refrigerators. Sellers market on multiple platforms, digital and traditional, including the brick and mortar store. Even the glossy catalogues that arrive in the mail still prompt sales.

Advancing technology has made it possible for consumers to shop not only across a staggering number of channels — but to do so in a constellation of ways. Say a shopper has broken down and decided to buy a wildly popular all-purpose pressure cooker. She might start off using the internet to glean product details and prescreen options. Then she might visit a retail outlet to eyeball the product herself. Finally, after mulling for days, she may impulsively whip out her phone to make the order.

But what determines these particular choices of shopping venues? Rice Business professor Utpal M. Dholakia set out to map this new landscape of consumerism. Joining Dholakia were colleagues Barbara E. Kahn of the Wharton Business School, Randy Reeves of Macy’s Department Stores, Aric Rindfleisch of the University of Wisconsin, David Stewart of the University of California at Riverside and Earl Taylor of the Marketing Science Institute.

Consumer behavior, the researchers knew, is too complex — too all-over-the-map — to develop any sort of quantum marketing theory to explain it. So while interested in answers, the team aimed instead to frame useful questions. Their goal was to bring attention to the multi-channel retailing environment, creating a comprehensive but flexible way to investigate how shoppers navigate the intricate modern marketplace.

More specifically, Dholakia’s team wanted to learn exactly what consumers are finding. What do they do while using various internet and other tools to shop? When do different types of shoppers grab their devices and buy? What obstacles crop up as shoppers wend their ways through this maze of venues? Finally, the researchers wanted to map the vast scope of research issues surrounding this customer behavior.

It was fairly simple to answer the first question: Why do we use such diverse shopping tactics? Usually, it’s about getting the best deal. Some people, however, take their shopping seriously, savoring the idea that they are approaching their task both thoughtfully and thoroughly. Others get a genuine thrill out of the social experience of being part of a community, or from experimenting with different products and ways to buy them. And some shoppers head straight to a certain website or media source because they expect a specific price tag.

Many consumers, Dholakia and his co-researchers found, constantly change the means they use to shop. In one survey of 337 multichannel shoppers, for example, the researchers found that 52 percent reported migrating back and forth from offline to online channels across four product categories including books, airline tickets, stereo systems and wine. This hopscotching from brick and mortar to catalogues, to online and back, could be predicted by certain factors including price, the product they were looking for, how they evaluated the product and even waiting time.

The researchers also found that each type of shopper uses channels differently. Penny-pinchers don’t care where they buy, as long as the price is right. Generalists shop online or in the store because of the overall shopping experience. Traditionalists shun new ways of shopping, and multichannel enthusiasts happily bounce between stores, the internet and catalogues. Finally, the hard-core, store-focused customers will only shop in a place with doors and shelves.

To add a layer of complication, some don’t use channels to shop at all. They just want information. These are the shoppers who pop into to a store to test drive a phone before they buy it online. They study the pressure cooker in a catalogue before they go to the store.

And even within all the online options, there are innumerable detours to explore. Say you want a Nikon camera. You might go to an enthusiasts’ page such as Nikonians.org before you decide which model to buy, whether it’s online or at the local camera shop. Your friendly chat with the guy who owns the local camera store may now turn into a real-time virtual chat with a company representative.

The new marketplace, in other words, has become a dizzying landscape. Shoppers, clearly, have risen to the challenge. Nevertheless, it’s in the interests of sellers and buyers both to understand more deeply not only why we buy what we buy — but where.

------

This article originally ran on Rice Business Wisdom and is based on research from Utpal M. Dholakia, the George R. Brown Professor of Marketing at Jones Graduate School of Business at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

Houston energy hub opens new fundraising cohort to fuel startups

Apply Now

EnergyTech Cypher has opened applications for its second Liftoff fundraising program.

Applications close May 20 for the 10-week virtual fundraising sprint. The program is geared toward energy and climatech founders preparing to raise their first institutional round. It will cover fundraising requisites, like pitch materials, term sheet negotiation and round closing, according to a release from EnergyTech Cypher.

The program kicks off June 1 and runs every Monday from 1-3 p.m. CST. It will conclude with an in-person capstone simulation in Houston on August 3, where founders will work to close a mock round.

Jason Ethier, EnergyTech Cypher founder and CEO, will lead the program with Payal Patel, an EnergyTech fellow and entrepreneur in residence.

The program is available through Cephyron, EnergyTech Cypher's new investor relationship management platform, built specifically for energy and climatech founders. Users must have a Cephyron Boost membership to participate in the Liftoff program.

The Cephyron IRM app recently went live and is available to founders at any point in their fundraising process, according to the news release. The platform aggregates investor data, tracks market signals and delivers curated weekly recommendations.

EnergyTech Cypher launched Liftoff last year. The inaugural cohort included 19 startups, including Houston-based AtmoSpark Technologies, The Woodlands-based Resollant and others. Each participant closed at least one fundraising deal, according to EnergyTech Cypher.

EnergyTech Cypher rebranded from EnergyTech Nexus earlier this year. It also launched its CoPilot accelerator in 2025. The inaugural group presented its first showcase during CERAWeek last month.

EnergyTech Cypher's annual Pilotathon Pilot Pitch and Showcase applications also opened this month. Find more information here.

---

This article originally appeared on EnergyCaptialHTX.com.

Cancer diagnostics startup wins top prize at annual Rice competition​

winner, winners

Rice University student-founded companies took home a total of $115,000 in equity-free funding at the annual Liu Idea Lab for Innovation and Entrepreneurship's H. Albert Napier Rice Launch Challenge last week.

2025 Rice Innovation Fellow Alexandria Carter won the top prize and $50,000 for her startup Bionostic. The startup offers personalized diagnostics for cancer patients by using 3D culturing through its Advanced Tumor Landscape Analysis System (ATLAS) platform.

Carter is working toward her PhD in bioengineering in Professor Michael King's laboratory. She recently completed the Rice Innovation Fellows program and plans to commercialize ATLAS, according to a news release from Rice.

Actile Technologies, founded by another former Rice Innovation Fellow, Barclay Jumet, won second place and $25,000. The company is developing and commercializing textile-integrated technologies. InnovationMap first covered Jumet's wearable technology back in 2023.

Kairos took home the third-place prize and $15,000, plus the $2,000 audience choice award and the $5,000 undergraduate business award. Founded last year by Sanjana Kavula and Adhira Tippur, Kairos is an AI-powered patient intake platform built specifically for independent dental practices.

The NRLC features top startups founded by undergraduate, graduate and MBA students at Rice each year. The top three finishers were named among a group of five finalists earlier this year, which also included HAAST Autonomous and Project Kestrel.

HAAST is developing an unmanned aircraft for organ transport, while Kestrel uses machine learning to organize bird photographers’ photo collections.

Teams presented multiple five-minute pitches throughout the application process over Zoom and in-person before the five finalists presented at the NRLC Championships April 21 at the Rice Memorial Center. Each finalist walked away with an equity-free investment.


Other awards went to:

UnitCode

  • $5,000 MBA Venture Award

HAAST Autonomous

  • $2,500 Chan-Kang Family Prize for Bold Ambition
  • $1,000 Healthcare Innovations Prize

Telstar Networks

  • $2,500 Outstanding Undergraduate Startup Award

Multiplay

  • $1,500 Frank Liu Jr. Prize for Creative Innovation in Music, Fashion, & the Arts

Butterfly Books

  • $1,500 Social Impact Award

SOOZ

  • $1,000 Interdisciplinary Innovation Prize sponsored by OURI

Dooly

  • $1,000 Consumer Goods Prize

Project Kestrel

  • $1,000 AI Prize

Veloci Running won the NRLC last year for its naturally shaped running shoe. Founder and CEO Tyler Strothman recently told InnovationMap that the company has gone on to sell roughly 10,000 pairs of its flagship Ascent shoe, designed to relieve lower leg tightness and absorb impact. Read more here.